Tandem Diabetes Care Announces Fourth Quarter 2022 Financial Results and Full Year 2023 Financial Guidance

Go back to Tandem Diabetes Care Announces Fourth Quarter 2022 Financial Results and Full Year 2023 Financial Guidance

Tandem Diabetes (TNDM) Tops Q4 EPS by 6c

February 22, 2023 4:16 PM EST

Tandem Diabetes (NASDAQ: TNDM) reported Q4 non-GAAP EPS of ($0.01), $0.06 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $223.4 million versus the consensus estimate of $221.6 million.

GUIDANCE:

Tandem Diabetes sees FY2023 revenue of $885-900 million, versus the... More